News | December 12, 2024
AbbVie completes acquisition of Aliada Therapeutics
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
The company uses iPS cells to develop treatments for diseases relating to the kidney
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Subscribe To Our Newsletter & Stay Updated
